Cite
Zhang JYJ, Zhang J, Kiffe M, et al. Preclinical Pharmacokinetics and Metabolism of MAK683, a Clinical Stage Selective Oral Embryonic Ectoderm Development (EED) Inhibitor for Cancer Treatment. Xenobiotica. 2021;1-48doi: 10.1080/00498254.2021.2005852.
Zhang, J. Y. J., Zhang, J., Kiffe, M., Walles, M., Jin, Y., Blanz, J., Dayer, J., Sanchez, A., Zhang, C., Zhang, L., Huang, Y., & Oyang, C. (2021). Preclinical Pharmacokinetics and Metabolism of MAK683, a Clinical Stage Selective Oral Embryonic Ectoderm Development (EED) Inhibitor for Cancer Treatment. Xenobiotica; the fate of foreign compounds in biological systems, 1-48. https://doi.org/10.1080/00498254.2021.2005852
Zhang, Ji Yue Jeff, et al. "Preclinical Pharmacokinetics and Metabolism of MAK683, a Clinical Stage Selective Oral Embryonic Ectoderm Development (EED) Inhibitor for Cancer Treatment." Xenobiotica; the fate of foreign compounds in biological systems vol. (2021): 1-48. doi: https://doi.org/10.1080/00498254.2021.2005852
Zhang JYJ, Zhang J, Kiffe M, Walles M, Jin Y, Blanz J, Dayer J, Sanchez A, Zhang C, Zhang L, Huang Y, Oyang C. Preclinical Pharmacokinetics and Metabolism of MAK683, a Clinical Stage Selective Oral Embryonic Ectoderm Development (EED) Inhibitor for Cancer Treatment. Xenobiotica. 2021 Nov 11;1-48. doi: 10.1080/00498254.2021.2005852. Epub 2021 Nov 11. PMID: 34761729.
Copy
Download .nbib